

Supplementary Table S7 - Univariate and multivariate analysis of factors affecting PFS in patients who received Cetuximab monotherapy (cohort 5).

Cohort 5 GSE5851 (N = 80)						
Variables	Univariate analysis^a			Multivariate analysis^b		
	N	PFS	P-value	HR	95% CI	P-value
Age^c			0.2			
<70 y	54	67.5%		—	—	—
≥ 70 y	24	32.5%		—	—	—
Gender**			0.009	1.542	0.9408–2.526	0.0858
Female	36	45%		1	—	—
Male	44	55%		—	—	—
YKL-40 Expression						
High	62	77.5%	0.005	1	—	—
Low	18	22.5%		1.920	1.0747–3.429	0.0276
EGFR Expression						
High	62	53.7%	0.018	1	—	—
Low	18	46.3%		1.714	1.0678–2.750	—
KRAS Mutation			0.2			
High	27	33.8%		—	—	—
Low	53	66.2%		—	—	—

a In univariate analyses, log-rank tests were conducted.

b In the multivariate Cox proportional hazard model, only variables with $P < 0.15$ in univariate analysis were included and the "enter method" was applied.

c Data on age of two patients were missing.